QR код

Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma

Abstract Background and Aim The purpose of this study was to analyze factors associated with the overall survival (OS) of atezolizumab/bevacizumab combination therapy for advanced hepatocellular carcinoma (aHCC). We also assessed the OS of patients with ineffective therapy and those who discontinued...

Повний опис

Збережено в:
Автори: Yoshihiko Yano, Atsushi Yamamoto, Takuya Mimura, Saeko Kushida, Seiya Hirohata, Seitetsu Yoon, Hirotaka Hirano, Soo Ki Kim, Yuri Hatazawa, Kenji Momose, Hiroki Hayashi, Takuo Kado, Katsuhisa Nishi, Hidenori Tanaka, Takanori Matsuura, Ryutaro Yoshida, Naoki Asaji, Eiichiro Yasutomi, Yuuki Shiomi, Akihiro Minami, Shohei Komatsu, Takumi Fukumoto, Yoshihide Ueda, Yuzo Kodama
Формат: Artigo
Мова:Inglês
Опубліковано: Wiley 2023-07-01
Серія:JGH Open
Предмети:
adverse event
hepatocellular carcinoma
immune checkpoint inhibitor
Онлайн доступ:https://doi.org/10.1002/jgh3.12932
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси